Cargando…
The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer
Several subsets of non-small cell lung cancer (NSCLC) are defined by the presence of oncogenic rearrangements that result in constitutive activation of a chimeric fusion protein. In NSCLCs that harbor ALK or ROS1 rearrangements, aberrant signaling from these fusion proteins can be overcome by potent...
Autores principales: | Dagogo-Jack, Ibiayi, Ritterhouse, Lauren L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815348/ https://www.ncbi.nlm.nih.gov/pubmed/33489818 http://dx.doi.org/10.21037/tlcr-2019-cnsclc-09 |
Ejemplares similares
-
How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)
por: Xia, Bing, et al.
Publicado: (2020) -
Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy
por: Suda, Kenichi, et al.
Publicado: (2020) -
Decade in review: a new era for RET-rearranged lung cancers
por: Choudhury, Noura J., et al.
Publicado: (2020) -
Targeting chimeras fusion proteins in non-small cell lung cancer: where are we going?
por: Passiglia, Francesco, et al.
Publicado: (2020) -
How selecting best upfront therapy for metastatic disease?—Focus on ROS1-rearranged disease
por: Landi, Lorenza, et al.
Publicado: (2020)